LeMaitre Vascular(US:LMAT)2026-02-25 23:02Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, a gross margin of 71.7%, and a 47% increase in operating income [4] - Q4 fully diluted earnings per share were $0.68, representing a 39% year-over-year increase [8] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [9] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4][9] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The company plans to consolidate its Chicago RFA facility into Burlington in 2026 to simplify operations and reduce costs [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating 12% sales growth and 21% adjusted operating income growth [6][11] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [9][10] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [10] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [9] Q&A Session Summary Question: Can you rank the factors key to achieving operating growth? - Management highlighted stable headcount, sales pricing growth, and improved manufacturing efficiency as key factors for operating leverage [16] Question: What contributed to the smoother price transition this year? - Management noted that sending price lists earlier allowed for better preparation among sales and customer service teams, leading to a smoother transition [17] Question: What is the setup for M&A in 2026? - Management indicated a focus on organic growth but remains open to M&A opportunities, particularly in the open vascular area [28][30] Question: Can you elaborate on the performance of Artegraft? - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [33] Question: How is the company performing in China? - Management reported a 24% revenue increase in Q4, with profitability achieved for the first time in the region [47] Question: What is the outlook for gross margin in 2026? - Management expects gross margin to increase by 170 basis points from 2025 to 2026, driven by pricing increases and manufacturing efficiencies [75] Question: What is the anticipated impact of the Restore Flow manufacturing transfer? - Management indicated it may be a slight headwind to margins in 2026 as operations transition [96]